MV Capital Management Inc. Sells 565 Shares of Pfizer Inc. (NYSE:PFE)

MV Capital Management Inc. decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.8% in the fourth quarter, Holdings Channel.com reports. The fund owned 6,689 shares of the biopharmaceutical company’s stock after selling 565 shares during the period. MV Capital Management Inc.’s holdings in Pfizer were worth $177,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC bought a new stake in shares of Pfizer in the 4th quarter worth about $26,000. Rialto Wealth Management LLC purchased a new stake in shares of Pfizer in the fourth quarter worth approximately $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer during the 4th quarter worth approximately $28,000. Noble Wealth Management PBC bought a new stake in shares of Pfizer during the fourth quarter worth $31,000. Finally, Curio Wealth LLC purchased a new stake in shares of Pfizer during the fourth quarter valued at $32,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Up 0.8 %

PFE stock opened at $25.20 on Friday. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The firm has a 50-day simple moving average of $26.06 and a 200-day simple moving average of $26.94. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $142.93 billion, a P/E ratio of 17.87, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.10 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Truist Financial dropped their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Citigroup reduced their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. UBS Group reduced their target price on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Finally, Bank of America reiterated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research note on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.